Arturo leads early-stage investments and company creation at Ysios Capital, driving the firm’s early-stage initiative.
Previously, he worked at M Ventures and most recently at Wellington Parties, where he was involved in multiple financings including Riffyn (acquired by Siemens), Plexium, eGenesis, Themis Biosciences (acquired by MSD) and Seamless Therapeutics, among others.
In 2022, Arturo played a pivotal role in the creation of Seamless Therapeutics, a pioneering gene editing company developing programmable recombinases for therapeutic applications and joined the company at launch, leading business development and corporate strategy from inception through several key milestones and securing a collaboration with Lilly valued at over $1.1B.
Arturo is also actively involved in the European life sciences start-up ecosystem, mentoring within several programs including the BII Advisory Group, among others. He is also one of the founders of the YVC Collective, one of the largest pan-European associations of emerging life science venture capital investors.
Arturo holds a BSc in Human Biology, an MSc in Biomedical Research, an MBA, and a PhD in Biomedicine.
